Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
Abstract Objective To compare the chemoresistance and survival in patients with stage IIIC or IV epithelial ovarian cancer who were treated with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) or primary debulking surgery (PDS). The clinical characteristics of patients w...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-09-01
|
| Series: | Journal of Ovarian Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13048-019-0562-9 |
| _version_ | 1828076941893173248 |
|---|---|
| author | Yan Gao Yuan Li Chunyu Zhang Jinsong Han Huamao Liang Kun Zhang Hongyan Guo |
| author_facet | Yan Gao Yuan Li Chunyu Zhang Jinsong Han Huamao Liang Kun Zhang Hongyan Guo |
| author_sort | Yan Gao |
| collection | DOAJ |
| description | Abstract Objective To compare the chemoresistance and survival in patients with stage IIIC or IV epithelial ovarian cancer who were treated with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) or primary debulking surgery (PDS). The clinical characteristics of patients who benefited from NACT were further evaluated. Methods We retrospectively analyzed 220 patients who underwent NACT followed by IDS or PDS from January 2002 to December 2016. Differences in clinicopathological features, chemoresistance and prognosis were analyzed. Results The incidence rate for optimal cytoreduction and chemoresistance in the NACT group was relatively higher than PDS group. No differences were observed in progression free survival or overall survival. Patients without macroscopic RD in NACT group (NACT-R0) had a similar prognosis compared to those in PDS group who had RD<1 cm, and a relatively better prognosis compared to the PDS group that had RD ≥ 1 cm. The survival curve showed that patients in NACT-R0 group that were chemosensitive seemed to have a better prognosis compared to patients in PDS group that had RD. Conclusion Patients without RD after PDS had the best prognosis, whereas patients with RD after NACT followed by IDS had the worst. However, even if patients achieved no RD, their prognosis varied depending on chemosensitivity. Survival was better in patients who were chemosensitive compared to thosewho underwent PDS but had RD. Hence evaluating the chemosensitivity and feasibility of complete cytoreduction in advance is crucial. |
| first_indexed | 2024-04-11T02:22:17Z |
| format | Article |
| id | doaj.art-115a5ae16e13471d9858e595eb826de8 |
| institution | Directory Open Access Journal |
| issn | 1757-2215 |
| language | English |
| last_indexed | 2024-04-11T02:22:17Z |
| publishDate | 2019-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Ovarian Research |
| spelling | doaj.art-115a5ae16e13471d9858e595eb826de82023-01-02T23:16:17ZengBMCJournal of Ovarian Research1757-22152019-09-011211810.1186/s13048-019-0562-9Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective studyYan Gao0Yuan Li1Chunyu Zhang2Jinsong Han3Huamao Liang4Kun Zhang5Hongyan Guo6Department of Obstetrics & Gynecology, Peking University Third HospitalDepartment of Obstetrics & Gynecology, Peking University Third HospitalDepartment of Obstetrics & Gynecology, Peking University Third HospitalDepartment of Obstetrics & Gynecology, Peking University Third HospitalDepartment of Obstetrics & Gynecology, Peking University Third HospitalDepartment of Obstetrics & Gynecology, Peking University Third HospitalDepartment of Obstetrics & Gynecology, Peking University Third HospitalAbstract Objective To compare the chemoresistance and survival in patients with stage IIIC or IV epithelial ovarian cancer who were treated with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) or primary debulking surgery (PDS). The clinical characteristics of patients who benefited from NACT were further evaluated. Methods We retrospectively analyzed 220 patients who underwent NACT followed by IDS or PDS from January 2002 to December 2016. Differences in clinicopathological features, chemoresistance and prognosis were analyzed. Results The incidence rate for optimal cytoreduction and chemoresistance in the NACT group was relatively higher than PDS group. No differences were observed in progression free survival or overall survival. Patients without macroscopic RD in NACT group (NACT-R0) had a similar prognosis compared to those in PDS group who had RD<1 cm, and a relatively better prognosis compared to the PDS group that had RD ≥ 1 cm. The survival curve showed that patients in NACT-R0 group that were chemosensitive seemed to have a better prognosis compared to patients in PDS group that had RD. Conclusion Patients without RD after PDS had the best prognosis, whereas patients with RD after NACT followed by IDS had the worst. However, even if patients achieved no RD, their prognosis varied depending on chemosensitivity. Survival was better in patients who were chemosensitive compared to thosewho underwent PDS but had RD. Hence evaluating the chemosensitivity and feasibility of complete cytoreduction in advance is crucial.http://link.springer.com/article/10.1186/s13048-019-0562-9Advanced ovarian epithelial CancerNeoadjuvant chemotherapyPrimary Debulking surgeryChemoresistancePrognosis |
| spellingShingle | Yan Gao Yuan Li Chunyu Zhang Jinsong Han Huamao Liang Kun Zhang Hongyan Guo Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study Journal of Ovarian Research Advanced ovarian epithelial Cancer Neoadjuvant chemotherapy Primary Debulking surgery Chemoresistance Prognosis |
| title | Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study |
| title_full | Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study |
| title_fullStr | Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study |
| title_full_unstemmed | Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study |
| title_short | Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study |
| title_sort | evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer a retrospective study |
| topic | Advanced ovarian epithelial Cancer Neoadjuvant chemotherapy Primary Debulking surgery Chemoresistance Prognosis |
| url | http://link.springer.com/article/10.1186/s13048-019-0562-9 |
| work_keys_str_mv | AT yangao evaluatingthebenefitsofneoadjuvantchemotherapyforadvancedepithelialovariancanceraretrospectivestudy AT yuanli evaluatingthebenefitsofneoadjuvantchemotherapyforadvancedepithelialovariancanceraretrospectivestudy AT chunyuzhang evaluatingthebenefitsofneoadjuvantchemotherapyforadvancedepithelialovariancanceraretrospectivestudy AT jinsonghan evaluatingthebenefitsofneoadjuvantchemotherapyforadvancedepithelialovariancanceraretrospectivestudy AT huamaoliang evaluatingthebenefitsofneoadjuvantchemotherapyforadvancedepithelialovariancanceraretrospectivestudy AT kunzhang evaluatingthebenefitsofneoadjuvantchemotherapyforadvancedepithelialovariancanceraretrospectivestudy AT hongyanguo evaluatingthebenefitsofneoadjuvantchemotherapyforadvancedepithelialovariancanceraretrospectivestudy |